

TDMS No. 99037 - 06

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 08/11/2010

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

F2_M3

C Number: C99037B
Lock Date: 11/20/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: 25022 ACCK
25019 MSAC
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.2.0

25021 TSAC
25018 DACC

25020 NATD

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
------------------	---------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50	50
Early Deaths					
Dosing Accident		1			
Moribund Sacrifice	3		4	4	
Natural Death	7	7	5	9	36
Survivors					
Natural Death					1
Terminal Sacrifice	40	42	41	37	13
Animals Examined Microscopically	50	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)	(50)
Inflammation, Acute		1 [3.0]			
Ulcer		1 [4.0]			
Submucosa, Edema		1 [2.0]			
Intestine Small, Duodenum	(48)	(46)	(50)	(46)	(48)
Ulcer				1 [2.0]	
Intestine Small, Ileum	(50)	(48)	(48)	(47)	(49)
Epithelium, Hyperplasia		1 [3.0]			
Intestine Small, Jejunum	(48)	(46)	(49)	(46)	(43)
Inflammation, Chronic Active				1 [3.0]	
Liver	(50)	(50)	(50)	(50)	(50)
Basophilic Focus	2	1		5	2
Clear Cell Focus	17	14	13	21	6
Cyst		1 [3.0]			
Eosinophilic Focus	2	5	5	5	
Eosinophilic Focus, Multiple			1		
Hematopoietic Cell Proliferation	1 [1.0]			1 [4.0]	
Hemorrhage				1 [2.0]	
Inflammation, Chronic					1 [3.0]
Inflammation, Chronic Active	2 [1.5]	1 [3.0]	3 [2.3]	3 [3.0]	1 [1.0]
Mixed Cell Focus	12	7	11	7	3
Necrosis, Focal	4 [3.0]		5 [2.0]	3 [2.3]	3 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Necrosis, Diffuse Tension Lipidosis	1 [2.0]		1	1 [3.0]	1 [4.0]
Centrilobular, Necrosis		2 [2.5]	1 [3.0]		
Hepatocyte, Hypertrophy					1 [2.0]
Hepatocyte, Vacuolization Cytoplasmic	23 [3.0]	13 [2.7]	20 [3.0]	17 [2.8]	5 [3.0]
Kupffer Cell, Hyperplasia			1 [3.0]		
Kupffer Cell, Pigmentation				1 [3.0]	
Mesentery	(4)	(4)	(3)	(7)	(3)
Fat, Necrosis	3 [2.3]	3 [4.0]	2 [3.0]	6 [2.7]	3 [2.7]
Pancreas	(50)	(50)	(50)	(50)	(50)
Atrophy		3 [2.7]	1 [1.0]	2 [2.5]	1 [1.0]
Basophilic Focus			2		
Acinus, Cytoplasmic Alteration	2 [3.0]	6 [2.8]	3 [3.0]	1 [3.0]	
Acinus, Hyperplasia, Focal	1 [1.0]		1 [1.0]		
Salivary Glands	(50)	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte	3 [3.0]	10 [2.6]	4 [2.3]	3 [2.3]	1 [2.0]
Stomach, Forestomach	(50)	(50)	(50)	(50)	(50)
Diverticulum		1			
Inflammation, Chronic	4 [1.8]	5 [1.8]	3 [2.7]	3 [1.3]	2 [3.0]
Ulcer	1 [2.0]	1 [2.0]			
Epithelium, Hyperplasia	7 [2.6]	7 [2.6]	8 [2.8]	3 [2.0]	5 [2.6]
Stomach, Glandular	(50)	(50)	(50)	(49)	(50)
Cyst	1 [3.0]	3 [3.0]	1 [3.0]		
Erosion	2 [1.5]	1 [2.0]	1 [3.0]	1 [2.0]	
Epithelium, Hyperplasia	1 [2.0]		1 [3.0]		1 [2.0]
Epithelium, Metaplasia, Squamous				1 [1.0]	
Tongue	(1)	(0)	(0)	(1)	(0)

CARDIOVASCULAR SYSTEM

Heart	(50)	(50)	(50)	(50)	(50)
Cardiomyopathy		2 [1.0]		1 [1.0]	
Inflammation, Chronic Active				1 [2.0]	
Mineralization	1 [1.0]				
Thrombosis	1 [4.0]				

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	4 [3.0]	5 [3.0]	7 [3.0]	2 [3.0]	4 [3.0]
Cyst					1 [1.0]
Degeneration, Fatty		1 [2.0]			1 [1.0]
Hyperplasia, Focal	5 [1.6]	7 [1.7]	5 [2.0]	2 [1.0]	1 [3.0]
Hypertrophy, Focal	16 [1.3]	20 [1.9]	20 [1.5]	14 [1.4]	2 [1.5]
Subcapsular, Hyperplasia	11 [2.4]	7 [2.1]	4 [2.5]	7 [2.1]	4 [2.0]
Adrenal Medulla	(49)	(49)	(50)	(50)	(50)
Hyperplasia		2 [1.5]	1 [2.0]		
Islets, Pancreatic	(50)	(50)	(50)	(50)	(50)
Atrophy				1 [4.0]	
Hyperplasia	12 [2.3]	8 [2.0]	12 [1.7]	10 [1.8]	3 [1.3]
Parathyroid Gland	(43)	(48)	(47)	(46)	(48)
Cyst				4 [3.0]	
Pituitary Gland	(48)	(50)	(48)	(49)	(49)
Pars Distalis, Cyst	4 [3.0]	3 [3.0]	2 [3.0]	2 [3.0]	
Pars Distalis, Hyperplasia, Focal	1 [1.0]	2 [1.0]	1 [1.0]		
Rathke's Cleft, Dilatation					2 [1.0]
Thyroid Gland	(49)	(50)	(50)	(49)	(50)
Follicle, Cyst				1 [3.0]	
Follicle, Degeneration, Focal	13 [1.5]	10 [1.7]	11 [1.8]	16 [1.8]	6 [1.3]
Follicular Cell, Hyperplasia		1 [2.0]			

GENERAL BODY SYSTEM

Tissue NOS	(1)	(1)	(1)	(1)	(0)
------------	-----	-----	-----	-----	-----

GENITAL SYSTEM

Epididymis	(50)	(50)	(50)	(50)	(50)
Granuloma Sperm		2 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Inflammation, Chronic Spermatocele		1 [2.0]		1 [2.0]	
Penis	(1)	(0)	(0)	(1)	(0)
Cyst				1 [3.0]	
Preputial Gland	(49)	(49)	(50)	(50)	(50)
Cyst	12 [3.0]	15 [3.0]	7 [3.0]	17 [3.0]	3 [3.0]
Inflammation, Chronic	13 [2.5]	11 [2.4]	10 [2.6]	10 [2.3]	5 [2.4]
Prostate	(49)	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte			1 [3.0]		
Seminal Vesicle	(50)	(50)	(50)	(50)	(50)
Testes	(50)	(50)	(50)	(50)	(50)
Angiectasis		1 [3.0]			
Germinal Epithelium, Atrophy		4 [2.0]	2 [1.0]	1 [2.0]	
Interstitial Cell, Hyperplasia			1 [3.0]		

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)	(50)
Hyperplasia	23 [2.5]	25 [2.4]	23 [2.5]	21 [2.8]	7 [2.7]
Lymph Node	(3)	(0)	(1)	(1)	(0)
Lymph Node, Mandibular	(47)	(49)	(46)	(47)	(44)
Atrophy	1 [3.0]	1 [3.0]	1 [2.0]		
Hemorrhage				1 [2.0]	
Hyperplasia, Lymphoid	5 [2.2]	1 [2.0]	9 [1.9]	5 [1.8]	1 [2.0]
Infiltration Cellular, Plasma Cell	1 [3.0]				
Pigmentation		2 [3.0]		1 [3.0]	
Lymph Node, Mesenteric	(49)	(48)	(47)	(47)	(50)
Angiectasis	1 [2.0]	2 [3.5]	3 [2.7]		
Atrophy	1 [3.0]	1 [2.0]	1 [2.0]	3 [2.3]	
Ectasia		1 [2.0]		1 [2.0]	
Hematopoietic Cell Proliferation	2 [2.0]	2 [2.0]		2 [2.0]	
Hemorrhage	6 [2.3]	4 [2.5]	6 [2.0]	2 [1.0]	1 [1.0]
Hyperplasia, Lymphoid	2 [2.0]	5 [2.6]	4 [2.0]	5 [2.0]	3 [2.7]
Infiltration Cellular, Plasma Cell				1 [2.0]	
Pigmentation		1 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Spleen	(50)	(50)	(50)	(49)	(50)
Accessory Spleen		1			
Angiectasis		1 [2.0]			
Hematopoietic Cell Proliferation	20 [2.7]	26 [2.8]	24 [2.8]	25 [2.8]	9 [2.4]
Pigmentation					1 [3.0]
Lymphoid Follicle, Atrophy	2 [2.5]	1 [3.0]	3 [3.0]	1 [3.0]	
Lymphoid Follicle, Hyperplasia	1 [1.0]	5 [1.6]	5 [2.0]	3 [1.7]	1 [2.0]
Thymus	(44)	(43)	(44)	(40)	(49)
Atrophy	3 [2.0]	8 [2.6]	4 [2.5]	6 [2.8]	2 [2.5]
Cyst	1 [3.0]	2 [3.0]	1 [3.0]	4 [3.0]	
Hyperplasia, Lymphoid	1 [3.0]	1 [3.0]		1 [3.0]	

INTEGUMENTARY SYSTEM

Skin	(50)	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion		2			
Edema		1 [2.0]	1 [3.0]	2 [2.5]	
Fibrosis			1 [4.0]		
Inflammation, Chronic			1 [2.0]		
Ulcer		2 [3.5]		2 [4.0]	
Epidermis, Hyperplasia			2 [2.0]	1 [4.0]	

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(49)	(50)
Hyperostosis	1 [3.0]	1 [2.0]			
Cranium, Osteopetrosis	1 [2.0]	1 [2.0]		2 [3.0]	
Skeletal Muscle	(2)	(1)	(3)	(1)	(0)

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)	(50)
Necrosis				1 [3.0]	
Pigmentation					1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
------------------	---------	---------	---------	----------	----------

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)	(50)
Foreign Body			1		1
Hemorrhage	2 [1.5]	1 [1.0]	1 [1.0]		5 [1.2]
Infiltration Cellular, Histiocyte		1 [2.0]	1 [2.0]	1 [2.0]	
Inflammation, Chronic Active		1 [1.0]			
Metaplasia, Osseous		1 [1.0]	1 [1.0]		1 [1.0]
Thrombosis				2 [1.5]	
Alveolar Epithelium, Hyperplasia	3 [1.3]	1 [1.0]	5 [1.4]	4 [2.3]	
Nose	(50)	(50)	(50)	(50)	(50)
Foreign Body		2	1	2	
Inflammation, Chronic	5 [1.4]	3 [1.3]	4 [1.3]	3 [1.7]	2 [1.5]
Respiratory Epithelium, Hyperplasia	1 [2.0]				

SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(50)	(50)
Atrophy	1 [4.0]				
Cataract		1 [2.0]			
Inflammation, Chronic		3 [2.3]	2 [2.0]		1 [3.0]
Cornea, Hyperplasia		2 [1.5]	1 [2.0]		
Cornea, Ulcer					1 [3.0]
Harderian Gland	(50)	(50)	(50)	(50)	(49)
Atrophy				1 [3.0]	
Hyperplasia, Focal	1 [2.0]	4 [2.0]		2 [2.0]	

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)	(50)
Cyst	11 [2.9]	15 [3.0]	9 [3.0]	9 [3.0]	1 [2.0]
Hydronephrosis		1 [2.0]			1 [2.0]
Infarct	2 [2.5]	3 [2.7]	6 [1.5]	5 [1.6]	1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Infiltration Cellular, Lymphocyte	1 [3.0]	6 [2.8]	5 [2.4]	5 [2.2]	1 [3.0]
Metaplasia, Osseous	2 [2.0]		5 [2.0]	6 [1.7]	1 [1.0]
Necrosis			1 [3.0]		
Nephropathy	40 [1.4]	41 [1.7]	38 [1.5]	38 [1.4]	16 [1.4]
Artery, Inflammation, Chronic Active				1 [3.0]	
Papilla, Necrosis					1 [2.0]
Renal Tubule, Dilatation, Focal					1 [2.0]
Renal Tubule, Hyperplasia					1 [2.0]
Renal Tubule, Pigmentation	1 [2.0]	3 [2.7]		1 [3.0]	
Urethra	(0)	(1)	(0)	(0)	(0)
Hemorrhage		1 [4.0]			
Inflammation, Acute		1 [3.0]			
Urinary Bladder	(50)	(50)	(50)	(50)	(50)
Dilatation		1 [4.0]		1 [4.0]	
Infiltration Cellular, Lymphocyte	2 [2.0]				
Transitional Epithelium, Hyperplasia					1 [2.0]

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
--------------------	---------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50	50
Early Deaths					
Accidentally Killed	2				1
Dosing Accident		6			4
Moribund Sacrifice	4	4	2	3	8
Natural Death	7	6	8	6	37
Survivors					
Natural Death			1		
Terminal Sacrifice	37	33	39	41	
Animals Examined Microscopically	50	49	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(48)	(49)	(50)	(50)
Inflammation, Acute		6 [3.7]			4 [2.8]
Ulcer		4 [4.0]			2 [2.5]
Submucosa, Edema			1 [2.0]		1 [2.0]
Gallbladder	(43)	(39)	(43)	(46)	(46)
Inflammation, Acute	1 [1.0]				
Pigmentation				2 [4.0]	
Epithelium, Cytoplasmic Alteration	1 [2.0]				
Intestine Large, Cecum	(48)	(46)	(46)	(49)	(49)
Edema				2 [3.0]	
Intestine Small, Duodenum	(46)	(44)	(45)	(46)	(48)
Diverticulum				1	
Intestine Small, Ileum	(48)	(47)	(45)	(49)	(48)
Epithelium, Hyperplasia				1 [3.0]	
Intestine Small, Jejunum	(47)	(47)	(45)	(48)	(47)
Hyperplasia, Lymphoid	1 [3.0]			1 [3.0]	
Epithelium, Hyperplasia	1 [3.0]				
Liver	(50)	(49)	(49)	(50)	(50)
Angiectasis	1 [3.0]		1 [1.0]		
Basophilic Focus	1	2		4	
Clear Cell Focus	3	2	4	2	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Cyst	1 [3.0]				
Eosinophilic Focus	3	3	3	4	
Hematopoietic Cell Proliferation	3 [2.7]	3 [2.3]	3 [2.0]	2 [2.5]	
Infiltration Cellular, Lymphocyte	2 [2.5]	1 [3.0]		4 [2.0]	
Inflammation, Chronic Active	4 [1.3]	3 [2.3]	2 [2.0]	7 [1.6]	
Mixed Cell Focus	1	5		5	
Necrosis, Focal	2 [2.5]	6 [1.7]	3 [1.3]		2 [1.0]
Necrosis, Diffuse		1 [2.0]		1 [1.0]	
Tension Lipidosis	1	1	2	1	
Centrilobular, Necrosis		1 [1.0]	2 [2.5]		
Hepatocyte, Hyperplasia, Focal			1 [2.0]		
Hepatocyte, Vacuolization Cytoplasmic	7 [2.9]	3 [3.7]	2 [3.5]	2 [3.5]	
Kupffer Cell, Hyperplasia	2 [2.5]	1 [2.0]	1 [3.0]	1 [3.0]	
Mesentery	(10)	(6)	(5)	(6)	(0)
Necrosis	1 [2.0]				
Fat, Necrosis	8 [2.6]	6 [3.3]	3 [3.0]	6 [3.2]	
Pancreas	(48)	(49)	(48)	(50)	(50)
Atrophy	2 [2.5]	1 [1.0]	2 [4.0]	1 [4.0]	1 [1.0]
Basophilic Focus	1	1	1		
Cyst	1 [3.0]		2 [3.0]	3 [3.0]	
Infiltration Cellular, Lymphocyte	3 [3.0]		1 [2.0]	1 [3.0]	
Acinus, Cytoplasmic Alteration	2 [3.0]		1 [2.0]		
Salivary Glands	(49)	(48)	(49)	(50)	(50)
Infiltration Cellular, Lymphocyte	11 [2.6]	13 [2.4]	19 [2.5]	13 [2.4]	
Stomach, Forestomach	(50)	(49)	(48)	(50)	(50)
Diverticulum		1	1		
Erosion				1 [1.0]	
Inflammation, Chronic			1 [2.0]		
Epithelium, Hyperplasia			1 [2.0]	2 [3.0]	1 [2.0]
Stomach, Glandular	(48)	(49)	(47)	(48)	(50)
Cyst	2 [3.0]	1 [3.0]	2 [3.0]	2 [3.0]	
Epithelium, Cytoplasmic Alteration				1 [2.0]	
Epithelium, Hyperplasia	1 [2.0]			1 [2.0]	
Tongue	(0)	(0)	(0)	(0)	(1)
Cyst					1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
CARDIOVASCULAR SYSTEM					
Heart	(50)	(49)	(50)	(50)	(50)
Cardiomyopathy		1 [3.0]			
Inflammation, Acute		2 [2.0]			
Mineralization	1 [1.0]	2 [1.0]	1 [2.0]	1 [3.0]	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(49)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	7 [3.0]	5 [3.0]	6 [3.0]	9 [3.0]	3 [3.0]
Amyloid Deposition				1 [3.0]	
Degeneration, Fatty	1 [3.0]			1 [3.0]	
Hyperplasia, Focal	2 [2.0]	1 [2.0]	1 [2.0]		
Hypertrophy, Focal			1 [2.0]	2 [3.0]	
Capsule, Hyperplasia	1 [2.0]	5 [1.8]		4 [1.8]	
Subcapsular, Cyst					1 [2.0]
Subcapsular, Hyperplasia, Focal				1 [2.0]	
Adrenal Medulla	(50)	(47)	(46)	(48)	(49)
Hyperplasia	1 [1.0]	1 [1.0]		1 [1.0]	
Islets, Pancreatic	(48)	(49)	(48)	(50)	(50)
Cyst		1 [2.0]			
Hyperplasia	1 [1.0]		2 [3.0]	4 [2.0]	
Parathyroid Gland	(45)	(42)	(46)	(47)	(49)
Cyst	2 [3.0]		1 [3.0]		4 [3.0]
Hyperplasia			1 [2.0]		
Pituitary Gland	(49)	(48)	(48)	(49)	(47)
Pars Distalis, Cyst	3 [3.0]	2 [3.0]		3 [3.0]	
Pars Distalis, Cytoplasmic Alteration, Focal	1 [2.0]				
Pars Distalis, Hemorrhage				1 [3.0]	
Pars Distalis, Hyperplasia, Focal	9 [1.7]	4 [1.5]	7 [1.4]	4 [2.0]	
Rathke's Cleft, Dilatation					1 [1.0]
Thyroid Gland	(50)	(48)	(48)	(49)	(49)
Artery, Inflammation, Chronic Active		1 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Follicle, Cyst	1 [3.0]	2 [3.0]			
Follicle, Degeneration, Focal Follicular Cell, Hyperplasia	28 [2.1]	15 [2.3]	28 [2.0]	23 [2.2] 3 [1.0]	2 [1.0]
GENERAL BODY SYSTEM					
Tissue NOS	(1)	(0)	(0)	(0)	(0)
GENITAL SYSTEM					
Clitoral Gland	(48)	(46)	(48)	(49)	(47)
Ovary	(48)	(47)	(49)	(48)	(50)
Amyloid Deposition				1 [3.0]	
Angiectasis	1 [3.0]	1 [3.0]	2 [4.0]	4 [2.8]	
Cyst	15 [3.0]	14 [3.0]	14 [3.0]	14 [3.0]	2 [3.5]
Hemorrhage	7 [2.3]	5 [2.0]	13 [2.2]	10 [2.1]	
Inflammation, Granulomatous		1 [3.0]			
Mineralization		1 [3.0]			
Pigmentation			2 [3.0]		
Thrombosis	1 [4.0]		1 [4.0]		
Granulosa Cell, Hyperplasia		1 [3.0]			
Uterus	(50)	(49)	(50)	(50)	(50)
Amyloid Deposition				1 [2.0]	
Angiectasis	1 [4.0]	1 [2.0]	2 [3.0]	4 [3.5]	
Infiltration Cellular, Histiocyte	1 [3.0]				
Inflammation, Suppurative	1 [3.0]				
Inflammation, Acute		1 [2.0]		1 [2.0]	
Necrosis				1 [3.0]	
Pigmentation	1 [3.0]				
Thrombosis	1 [3.0]	1 [4.0]	1 [4.0]	1 [3.0]	
Endometrium, Hyperplasia, Cystic	39 [2.9]	26 [2.3]	34 [2.0]	35 [2.3]	15 [1.4]
Myometrium, Hypertrophy		1 [3.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(49)	(49)	(50)	(50)
Angiectasis		1 [3.0]			
Hyperplasia	19 [2.8]	20 [3.0]	13 [2.8]	16 [2.7]	5 [3.0]
Myelofibrosis		1 [2.0]			
Lymph Node	(6)	(3)	(3)	(1)	(0)
Bronchial, Atrophy		1 [4.0]			
Bronchial, Pigmentation		1 [3.0]			
Iliac, Ectasia	1 [4.0]				
Iliac, Hematopoietic Cell Proliferation	1 [2.0]				
Mediastinal, Atrophy		1 [4.0]			
Mediastinal, Ectasia	1 [3.0]				
Mediastinal, Pigmentation		1 [3.0]			
Lymph Node, Mandibular	(48)	(46)	(45)	(48)	(49)
Atrophy	1 [2.0]				
Hematopoietic Cell Proliferation	2 [2.0]		1 [2.0]		1 [1.0]
Hyperplasia, Lymphoid	9 [2.0]	6 [2.5]	7 [2.3]	2 [2.0]	3 [2.0]
Infiltration Cellular, Histiocyte				1 [2.0]	
Pigmentation	4 [3.0]	3 [3.0]	4 [3.0]	3 [3.0]	
Lymph Node, Mesenteric	(46)	(49)	(46)	(48)	(47)
Atrophy		2 [3.0]	1 [2.0]	1 [3.0]	1 [3.0]
Ectasia	1 [4.0]			2 [4.0]	
Hematopoietic Cell Proliferation			1 [2.0]	1 [3.0]	
Hemorrhage	2 [2.5]	4 [2.8]	1 [3.0]	4 [3.8]	
Hyperplasia, Lymphoid	6 [2.8]	6 [2.2]	2 [2.5]	7 [2.3]	
Infiltration Cellular, Histiocyte				1 [3.0]	
Necrosis		1 [3.0]			
Pigmentation	1 [3.0]			1 [3.0]	
Spleen	(50)	(49)	(48)	(50)	(50)
Amyloid Deposition	1 [3.0]				
Atrophy				1 [3.0]	
Hematopoietic Cell Proliferation	33 [2.4]	39 [2.6]	36 [2.4]	37 [2.2]	5 [2.4]
Pigmentation	1 [3.0]			1 [3.0]	1 [2.0]
Lymphoid Follicle, Atrophy				1 [3.0]	
Lymphoid Follicle, Hyperplasia	12 [2.3]	14 [2.5]	12 [2.4]	17 [2.4]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Thymus	(46)	(45)	(46)	(48)	(49)
Atrophy	4 [2.5]	8 [2.9]	5 [2.6]	6 [3.0]	3 [3.0]
Cyst		1 [3.0]			
Hemorrhage	1 [3.0]	1 [3.0]			
Hyperplasia, Lymphoid	6 [1.7]	1 [3.0]	2 [1.5]	4 [1.8]	1 [1.0]
Inflammation, Chronic Active		3 [3.7]			3 [3.0]

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(49)	(50)	(50)	(50)
Hyperplasia	5 [1.4]	5 [1.8]	3 [2.0]	6 [1.8]	
Skin	(50)	(49)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1	
Edema		1 [3.0]		1 [2.0]	
Hemorrhage					1 [3.0]
Inflammation, Chronic Active		1 [2.0]			
Ulcer	2 [2.5]	1 [4.0]			
Subcutaneous Tissue, Inflammation, Chronic Active		1 [3.0]			

MUSCULOSKELETAL SYSTEM

Bone	(50)	(49)	(50)	(50)	(50)
Fibrosis	1 [2.0]	2 [2.0]	1 [2.0]	3 [2.3]	
Fracture	1		2		
Femur, Hyperostosis	1 [3.0]				
Skeletal Muscle	(3)	(2)	(0)	(0)	(0)

NERVOUS SYSTEM

Brain	(50)	(49)	(50)	(50)	(50)
Compression	1 [4.0]			1 [4.0]	
Cyst Epithelial Inclusion	1				
Hemorrhage				1 [3.0]	1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Necrosis Artery, Meninges, Inflammation, Chronic Active	1 [2.0]	1 [2.0]		1 [2.0]	
RESPIRATORY SYSTEM					
Lung	(50)	(49)	(50)	(50)	(50)
Fibrosis		1 [3.0]			
Foreign Body		8			5
Hemorrhage	2 [2.5]		1 [2.0]	7 [1.9]	6 [1.7]
Infiltration Cellular, Histiocyte			1 [2.0]		
Infiltration Cellular, Lymphocyte	2 [2.5]		2 [2.0]	4 [2.3]	
Inflammation, Suppurative		1 [4.0]			
Inflammation, Granulomatous		1 [3.0]			
Inflammation, Acute		4 [3.5]	1 [3.0]		
Inflammation, Chronic	1 [2.0]				1 [2.0]
Inflammation, Chronic Active		2 [3.5]			1 [1.0]
Metaplasia, Osseous			1 [2.0]		
Thrombosis	1 [1.0]			1 [2.0]	
Alveolar Epithelium, Hyperplasia	1 [1.0]	1 [1.0]	1 [3.0]		
Arteriole, Hypertrophy					1 [2.0]
Nose	(50)	(49)	(50)	(50)	(50)
Foreign Body	1	4			
Inflammation, Chronic	2 [1.0]	4 [1.0]	2 [1.0]		
Pleura	(0)	(0)	(0)	(0)	(4)
Inflammation, Acute					4 [4.0]
Trachea	(50)	(49)	(50)	(50)	(50)
Inflammation, Chronic Active					1 [4.0]
SPECIAL SENSES SYSTEM					
Eye	(50)	(49)	(50)	(50)	(50)
Atrophy		1 [4.0]		1 [4.0]	
Cataract			2 [3.0]		
Inflammation, Chronic	1 [1.0]	2 [2.0]	2 [2.0]	2 [2.0]	
Cornea, Hyperplasia		1 [2.0]	2 [1.0]	1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: CHRONIC

alpha/beta Thujone mixture

Time Report Requested: 13:12:57

Route: GAVAGE

CAS Number: THUJONEMIXAB

First Dose M/F: 06/30/03 / 06/30/03

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Harderian Gland	(50)	(49)	(50)	(49)	(50)
Cyst			1 [3.0]		
Hyperplasia, Focal	1 [1.0]	1 [3.0]	1 [1.0]	1 [1.0]	
Infiltration Cellular, Lymphocyte			1 [3.0]		
URINARY SYSTEM					
Kidney	(50)	(49)	(49)	(50)	(50)
Amyloid Deposition				1 [4.0]	
Cyst	3 [3.0]	3 [3.0]		1 [3.0]	
Glomerulosclerosis		1 [3.0]			
Infarct	2 [2.5]	5 [2.4]	6 [1.8]	1 [1.0]	
Infiltration Cellular, Lymphocyte	3 [2.3]	9 [2.6]	5 [2.2]	5 [2.8]	
Inflammation, Chronic	1 [3.0]				
Metaplasia, Osseous	1 [3.0]	1 [2.0]	2 [1.5]	3 [2.3]	
Mineralization				1 [2.0]	
Nephropathy	11 [1.5]	11 [1.3]	5 [1.0]	7 [1.7]	3 [1.0]
Renal Tubule, Accumulation, Hyaline Droplet	1 [3.0]	2 [3.0]	1 [3.0]	2 [2.5]	
Renal Tubule, Cytoplasmic Alteration			1 [3.0]		
Renal Tubule, Pigmentation	1 [3.0]		2 [3.0]		
Urinary Bladder	(50)	(49)	(49)	(50)	(50)
Infiltration Cellular, Lymphocyte	2 [2.0]	1 [2.0]	2 [3.0]	4 [2.8]	

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)